About the Study
This clinical research study is designed to evaluate the safety and effectiveness of ReneuRx™, an investigational injection that is being researched to reduce hip pain associated with greater trochanteric pain syndrome. In this study, researchers will compare ReneuRx™ to corticosteroid injection. ReneuRx™ is considered investigational because it has not been approved by the Food and Drug Administration (FDA).
The study is randomized and single-blind to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 66% chance you will receive the study injection and a 34% you will receive the corticosteroid injection.
You will be in this study for up to 54 weeks, which will include a screening period, a treatment period, and a follow-up period. The study will require approximately 10 in-clinic visits. If you qualify and choose to participate, you may be compensated up to $1,250 for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.